ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 2710 • 2015 ACR/ARHP Annual Meeting

    Necrox-7 Inhibits Cell Aggressiveness By Suppressing of NF-Kappa B Activation and Reactive Oxygen Species Generation in Human Rheumatoid Arthritis Fibroblast-like Synoviocytes

    Hyun Jung Yoo1,2, Jin Kyun Park2, Eun Young Lee2, Eun Bong Lee2 and Yeong Wook Song2,3, 1Department of Molecular Medicine and Biopharmaceutical Sciences, BK21 plus Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, 3Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine Seoul National University, Seoul, South Korea

    Background/Purpose: Rheumatoid arthritis (RA) is characterized by hyperplastic synovial pannus tissue, which mediates destruction of cartilage and bone. Fibroblast-like synoviocytes (FLS) are a key component…
  • Abstract Number: 1618 • 2015 ACR/ARHP Annual Meeting

    The Protective Effect of HLA-DRB1*13 Alleles during Specific Phases in the Development of ACPA-Positive RA

    J. van Heemst1, A.H. Hensvold2, X. Jiang2, H. van Steenbergen1, L. Klareskog2, T. W. J. Huizinga1, A.H.M. van der Helm- van Mil1, A.I. Catrina2, René E. M. Toes1, K. Lundberg2 and Diane van der Woude1, 1Leiden University Medical Center, Leiden, Netherlands, 2Karolinska Institute, Stockholm, Sweden

    Background/Purpose: HLA-DRB1*13 alleles are associated with protection from anti-citrullinated protein antibody (ACPA-)positive rheumatoid arthritis (RA). It is however unknown at which phase of disease development…
  • Abstract Number: 2732 • 2015 ACR/ARHP Annual Meeting

    The Effect of Adrenocorticotropin Gel (HP Acthar Gel) in Combination with MTX in Newly Diagnosed RA Patients from a Clinical and Structural Perspective

    Norman B. Gaylis1, Steven Needell2 and Joanne Sagliani1, 1Arthritis & Rheumatic Disease Specialties, Aventura, FL, 2Boca Radiology Group, Boca Raton, FL

    Background/Purpose: Although adrenocorticotropin (ACTH) gel was approved by the FDA for the treatment of RA in 1952, data on its clinical and structural benefits for…
  • Abstract Number: 1622 • 2015 ACR/ARHP Annual Meeting

    Genome-Wide Association Analysis and Whole Genome Sequencing Identify Variants Associated with Radiographic Severity of Rheumatoid Arthritis in African Americans

    Vincent A. Laufer1, Richard J. Reynolds2, Maria I. Danila3, R. Curtis Hendrickson4, Elliot J. Lefkowitz5, Devin Absher6, Robert P. Kimberly7 and S. Louis Bridges Jr.8, 1Division of Clinical Rheumatology and Immunology, University of Alabama at Birmingham, Birmingham, AL, 2Medicine, University of Alabama at Birmingham, Birmingham, AL, 3AL, 4University of Alabama at Birmingham, Birmingham, AL, 5Microbiology, University of Alabama at Birmingham, Birmingham, AL, 6Hudson Alpha Institute for Biotechnology, Huntsville, AL, 7Medicine, Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 8Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Joint damage manifested by bony erosions and joint space narrowing is a major contributor to the morbidity and mortality of RA. Reports in Caucasians…
  • Abstract Number: 3098 • 2015 ACR/ARHP Annual Meeting

    Synovial Lymphocytic Aggregates Associate with Highly Active RA and Predict Erosive Disease at 12 Months: Results from the Pathobiology of Early Arthritis Cohort

    Maria DiCicco1, Frances Humby1, Stephen Kelly2, Rebecca Hands1, nora ng3, Arti Mahto3, Illias Lazarou3, Vidalba Rocher1, Lu Zou3, Michele Bombardieri4, Christopher Buckley5, A.H.M. van der Helm- van Mil6, Robert B.M. Landewé7, Désirée van der Heijde8, Iain B. McInnes9, Peter C. Taylor10 and Costantino Pitzalis11, 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, 2William Harvey Research Institute, Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, 3William Harvey Research Institute, Centre for Experimental Medicine and Rheumatology, London, United Kingdom, 4Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, 5University of Birmingham, Rheumatology Research Group, Birmingham, United Kingdom, 6Leiden University Medical Center, Leiden, Netherlands, 7University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands, 8Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 9Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 10Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom, 11Centre for Experimental Medicine & Rheumatology, Queen Mary's School of Medicine and Dentistry, London, United Kingdom

    Background/Purpose: The inflammatory cell infiltrate in RA synovium has been recognised to organise into lymphocytic aggregates (Ags) with data to suggest that these structures are…
  • Abstract Number: 1646 • 2015 ACR/ARHP Annual Meeting

    Which Factors Influence the Prescription of Tocilizumab Alone or in Combination with Dmards in Rheumatoid Arthritis Patients in a Real Life Setting? the ACT-Solo Study: An Analysis of Efficacy and Safety at 12 Months

    Jacques Tebib1, Isabelle Idier2, Mathieu Coudert3, David Pau4, Jean-Francis Maillefert5 and Rene-Marc Flipo6, 1Rheumatology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France, 2Chugai Pharma, La Defense, France, 3Statistics, Experis IT, Nanterre, France, 4Statistics, Roche, Boulogne-Billancourt, France, 5Rheumatology, University Hospital, Dijon, France, 6Rheumatology, University Hospital, Lille, France

    Background/Purpose: Baseline factors influencing the use of tocilizumab (TCZ) in monotherapy (Mono) instead of combination with DMARDs (Combo) in real-life practice in RA patients (pts)…
  • Abstract Number: 3136 • 2015 ACR/ARHP Annual Meeting

    Impact of Prokinetic Agents on Systemic Sclerosis-Associated Gastrointestinal Disease: A Systematic Review

    Annaliese Tisseverasinghe1, Ahmad Kadhim2, Ambica Parmar2, Louis Liu2 and Sindhu R. Johnson1, 1Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institue of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, 2Division of Gastroenterology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada

    Background/Purpose: More than 90% of patients with Systemic Sclerosis (SSc) have gastroinstestinal (GI) involvement, commonly dysmotility causing complications such as gastroesophageal reflux and constipation. Treatment…
  • Abstract Number: 1648 • 2015 ACR/ARHP Annual Meeting

    The Balance of Foxp3/Ror-Gammat Expression Is Altered By Tocilizumab and By Abatacept in Patients with Rheumatoid Arthritis

    Yoshifumi Tada1, Syuichi Koarada2, Nobuyuki Ono2, Akihito Maruyama2, Satoko Tashiro2, Yukiko Tokuda2, Yukihide Ono2, Yoshinobu Nakao2 and Akihide Ohta3, 1Department of Internal Medicine, Division of Rheumatology, Saga University, Saga, Japan, 2Rheumatology, Saga University, Saga, Japan, 3Department of Adult and Gerontological Nursing, Saga University School of Medicine, Saga, Japan

    Background/Purpose: It has been shown that the balance between Th17 cells and regulatory T (Treg) cells plays an important role for the development of autoimmune…
  • Abstract Number: 3191 • 2015 ACR/ARHP Annual Meeting

    Siglec9 Suppresses Arthritis in Collagen-Induced Mice Model and Inhibits M1 Activation of RAW264.7 Macrophages

    Takuya Matsumoto1, Nobunori Takahashi1, Toshihisa Kojima1 and Naoki Ishiguro2, 1Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, 2Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan

    Background/Purpose: Siglecs (Sialic acid-binding immunoglobulin-type lectins) are type1 transmembrane proteins and expressed on cell surface of various immunocytes. Siglec9 is a member of CD33 related…
  • Abstract Number: 2165 • 2014 ACR/ARHP Annual Meeting

    Myeloid-Derived Suppressor Cells in Rheumatoid Arthritis: Friend or Foe?

    Fanlei Hu1, Chunqing Guo2, Xiang-Yang Wang2 and Zhanguo Li1, 1Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, 2Department of Human and Molecular Genetics, Virginia Commonwealth University School of Medicine, Richmond, VA

    Background/Purpose Although myeloid-derived suppressor cells (MDSCs) have been linked to T-cell tolerance, their role in rheumatoid arthritis (RA) remains exclusive. Here, we investigated the potential…
  • Abstract Number: 519 • 2014 ACR/ARHP Annual Meeting

    Patterns of Tocilizumab Use and Safety in Patients with Rheumatoid Arthritis: Interim Results from a Multinational Observational Study

    Boulos Haraoui1, Gustavo Casado2, Elke Theander3, Laszlo Czirják4, Andrew Taylor5, Peter Button6, Lykke Hinsch Gylvin7 and Roberto Caporali8, 1Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, 2Hospital Militar Central, Buenos Aires, Argentina, 3Skane University Hospital Malmö, Lund University, Malmö, Sweden, 4University of Pécs, Pécs, Hungary, 5Royal Perth Hospital, Perth, Australia, 6Roche Products Pty Limited, Dee Why, Australia, 7F. Hoffmann-La Roche, Basel, Switzerland, 8Rheumatology, Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy

    Background/Purpose: Tocilizumab (TCZ) is indicated for the treatment of patients with RA who have had inadequate responses to DMARDs either as monotherapy (Mono) or in…
  • Abstract Number: 135 • 2014 ACR/ARHP Annual Meeting

    Comparison of the Ultrasonography Images and Synovial Pathology of the Joints in Patients with Rheumatoid Arthritis Treated with Biological Agents

    Asami Abe1, Hajime Ishikawa1 and Akira Murasawa2, 1Rheumatology, Niigata Rheumatic Center, Shibata, Japan, 2Niigata Rheumatic Center, Shibata, Japan

    Background/Purpose: An early diagnosis and tight disease control have increased in importance in the era of biological therapy for rheumatoid arthritis (RA).  Ultrasonography (US) of…
  • Abstract Number: 2879 • 2014 ACR/ARHP Annual Meeting

    Epigallocatechin-3-Gallate (EGCG) Suppresses IL-1β-Induced IL-6 and IL-8 Synthesis By Selectively Inhibiting TAK1 Activation in Human Rheumatoid Arthritis Synovial Fibroblasts

    Anil Singh1, Sharayah Riegsecker2, Sadiq Umar1 and Salahuddin Ahmed1, 1Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, 2Department of Pharmacology, University of Toledo, Toledo, OH

    Background/Purpose: In rheumatoid arthritis (RA), the role of interleukin-1β (IL-1β) signaling proteins (IRAK-1/TAK-1/TRAF-6) proximal to IL-1 receptor in mediating proinflammatory response is not completely understood.…
  • Abstract Number: 1972 • 2014 ACR/ARHP Annual Meeting

    Analysis of Anakinra in Primary Human Cell Systems Reveals an in Vitro Signature for Skin-Related Side Effects

    Ellen L. Berg, Alison O'Mahony and Mark A Polokoff, BioSeek, South San Francisco, CA

    Background/Purpose The therapeutic options for treatment of rheumatic diseases have grown and now include a variety of inflammatory pathway inhibitors, with diverse mechanisms, but having…
  • Abstract Number: 517 • 2014 ACR/ARHP Annual Meeting

    Real-World Use of Tocilizumab in Rheumatoid Arthritis Patients in Canada: Interim Results

    Boulos Haraoui1, Shahin Jamal2, Vandana Ahluwalia3, Tarang Manchanda4 and Majed Khraishi5, 1Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, 2Department of Rheumatology, University of British Columbia, Vancouver, BC, Canada, 3William Osler Health Center, Brampton, ON, Canada, 4Hoffmann-La Roche Canada, Mississauga, ON, Canada, 5Nexus Clinical Research, St John's, NF, Canada

    Background/Purpose Tocilizumab (TCZ) has been approved for the treatment of adults with rheumatoid arthritis (RA) either as monotherapy or as combination with disease-modifying antirheumatic drugs…
  • « Previous Page
  • 1
  • …
  • 175
  • 176
  • 177
  • 178
  • 179
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology